Recursion

Dive into Recursion's innovative approach to decoding biology. Join our mission & explore what AI drug discovery companies can do. Contact us

Recursion was founded more than a decade ago on the idea that we could take images of cells and use these images to train artificial intelligence to understand the vast unknown biological space – the cellular disruptions driving disease – to use AI-drug discovery to reduce the massive 90% failure rate of traditional drug discovery. Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas Leveraging the Power of Patient Data in AI-Drug Discovery Will AI ever cure cancer? The multibillion-dollar race to bring the first AI-discovered drug to market